Bayer Asset Gives Roivant Sciences’ New ‘Vant’ a Shot at Besting a United Therapeutics Lung Drug

Roivant Sciences subsidiary Pulmovant is on track for a Phase 2 test of mosliciguat as a treatment for pulmonary hypertension associated with interstitial lung disease. The inhaled drug offers a different mechanism of action and less burdensome dosing compared to United Therapeutics’ blockbuster PH-ILD drug, Tyvaso. The post Bayer Asset Gives Roivant Sciences’ New ‘Vant’…

Read More

Harris and Trump Are Ready To Take on Big Pharma

Former president Donald Trump and Vice President Kamala Harris are both eager to take on high drug prices, leaving pharmaceutical companies on the defensive as they spend millions of dollars this election season. When Harris was California’s attorney general, she joined cases that resulted in almost $7.2 billion (about $22 per person in the United…

Read More